ReviewCancer immunology, immunotherapy : CII2019
Opposing roles of eosinophils in cancer.
Review in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 121 citations in OpenAlex.
- Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study.Breast (Edinburgh, Scotland) · 2026Article
- Intraperitoneal Paclitaxel-Induced Eosinophil Recruitment as a Potential Mediator of Tumor Response in Peritoneal Metastases from Gastric Cancer.Annals of surgical oncology · 2026Article
- Impact of eosinophil levels on postoperative clinical outcomes in patients undergoing extracorporeal circulation: a retrospective cohort study.BMC cardiovascular disorders · 2026Article
- SMARCB1 (INI-1)-deficient carcinoma with eosinophilia and cervical lymph node metastasis of unknown primary: a case report and literature review.Frontiers in oncology · 2026Article
- Integrated risk stratification for ICI-associated myocarditis: a baseline hematological profile and a combined ECG and enzymatic signature at onset.Frontiers in immunology · 2026Article
- Mendelian Randomization Combined with Bioinformatics Revealed Specific Allergy-Mediated Protective Mechanisms Against Renal Cell Carcinoma.Phenomics (Cham, Switzerland) · 2025Article
- Eosinophil Dynamics as Prognostic Indicators in Immunotherapy for Pulmonary Lymphoepithelioma-Like Carcinoma.Cureus · 2025Article
- The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLCBiomolecules · 2025Review
- Harnessing myeloid cells in cancer.Molecular cancer · 2025Review
- Eosinophils as predictive biomarkers in anti-programmed cell death 1 monotherapy for non-small cell lung cancer.Frontiers in immunology · 2025Article
- Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer.NPJ precision oncology · 2024Article
- Unexpected Multiple Gastrointestinal Cancers in a Patient with Chronic Eosinophilia: A Case Report.Journal of gastrointestinal cancer · 2024Article
- SPINK5 is a key regulator of eosinophil extracellular traps in head and neck squamous cell carcinoma.Discover oncology · 2024Article
- Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis.Cancers · 2024Review
- Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events.Journal for immunotherapy of cancer · 2024Article
- Peripheral Inflammation Featuring Eosinophilia or Neutrophilia Is Associated with the Survival and Infiltration of Eosinophils within the Tumor among Various Histological Subgroups of Patients with NSCLC.International journal of molecular sciences · 2024Article
- Assessment of Tumor-Associated Tissue Eosinophilia (TATE) and Tumor-Associated Macrophages (TAMs) in Canine Transitional Cell Carcinoma of the Urinary Bladder.Animals : an open access journal from MDPI · 2024Article
- An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.Thoracic cancer · 2024Article
- The Enhanced Role of Eosinophils in Radiomics-Based Diagnosis of Microvascular Invasion and Its Association with the Immune Microenvironment in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Article
- Assessment of Tissue Eosinophilic Infiltration in Invasive Mammary Carcinoma.International journal of breast cancer · 2024Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Eosinophils are a subset of granulocytes mostly known for their ability to combat parasites and induce allergy. Although they were described to be related to cancer more than 100 years ago, their role in tumors is still undefined. Recent observations revealed that they display regulatory functions towards other immune cell subsets in the tumor microenvironment or direct cytotoxic functions against tumor cells, leading to either antitumor or protumor effects. This paradoxical role of eosinophils was suggested to be dependent on the different factors in the TME. In addition, the clinical relevance of these cells has been recently addressed. In most cases, the accumulation of eosinophils both in the tumor tissue, called tumor-associated tissue eosinophilia, and in the peripheral blood were reported to be prognostic markers for a better outcome of cancer patients. In immunotherapy of cancer, particularly in therapy with immune checkpoint inhibitors, eosinophils were even shown to be a potential predictive marker for a beneficial clinical response. A better understanding of their role in cancer progression will help to establish them as prognostic and predictive markers and to design strategies for targeting eosinophils.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.